Bradley Canino
Stock Analyst at Stifel
(1.64)
# 3,390
Out of 5,051 analysts
88
Total ratings
32.91%
Success rate
-1.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $15.10 | +191.39% | 7 | Sep 10, 2025 | |
| JANX Janux Therapeutics | Reinstates: Buy | $45 | $27.54 | +63.40% | 3 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $3.87 | +287.60% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.26 | +19.05% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $7.31 | +159.92% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $6.55 | +251.15% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $9.57 | +432.92% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $9.94 | +91.15% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $74.59 | -43.69% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $18.07 | +121.36% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $92.09 | +46.60% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $12.38 | +61.55% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.91 | +155.75% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.34 | +646.27% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $95.18 | +4.01% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.37 | +490.72% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $59.89 | -8.16% | 4 | Feb 23, 2024 |
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $15.10
Upside: +191.39%
Janux Therapeutics
Sep 10, 2025
Reinstates: Buy
Price Target: $45
Current: $27.54
Upside: +63.40%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $3.87
Upside: +287.60%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.26
Upside: +19.05%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $7.31
Upside: +159.92%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $6.55
Upside: +251.15%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $9.57
Upside: +432.92%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $9.94
Upside: +91.15%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $74.59
Upside: -43.69%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $18.07
Upside: +121.36%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $92.09
Upside: +46.60%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $12.38
Upside: +61.55%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $3.91
Upside: +155.75%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.34
Upside: +646.27%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $95.18
Upside: +4.01%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.37
Upside: +490.72%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $59.89
Upside: -8.16%